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1.0 INTRODUCTION/BACKGROUND
A`.
In order to minimize launch requirements necessary to
Y-
	meet the demands of future long-term spaceflight, NASA will
reuse water reclaimed from various on-board sources including
urine, feces, wash water and humidity condensate. Develop-
ment of reclamation systems through actual flight qualifica-
tion requires the promulgation of water quality standards
for potable reuse of the reclaimed water.
Existing standards for domestic U.S. potable water
consumption have been developed by the United States Public
Health Service (USPHS), and more recently the Environmental
Protection Agency (EPA). Earlier standards evolved over
many years of real use experience in which it was determined
that waters containing less than the specified amounts of a
particular constituent were acceptable for human consumption.
In more recent years the EPA has conducted extensive analyt-
ical studies of potable water supplies and performed corollary
epidemiological and toxicological investigations. However,
neither the old USPHS standards or newly proposed EPA standards
consider the peculiar problems associated with the potable
reuse of recycled water. The need for a study effort to
develop a protocol (or management plan) leading to the
establishment of potable reuse water standards has been
recognized by NASA. This report gives the results of
this study effort.
NAS9-15368	
-2-
The most mature technique for recovery of potable water
from urine and humidity condensate aboard spacecraft is vapor
compression distillation or VCD. The process employs motor-
driven evacuated rotating concentric cylinders to provide
artificial gravity for boiling and condensing at low pressure.
Energy efficiency is obtained by compressing the vapor and
allowing it to condense at a higher temperature on the
opposite side of the boiling surface. Latent heat is thus
recycled and the only input energy required is that needed
to overcome dynamic friction and provide for thermodynamic
work.
The NASA recognizes that any water quality standards
program for spacecraft must be based to a great extent on
knowledge of the potential contaminants associated with
reclamation systems and their associated health hazards.
Previously funded study efforts have developed and applied
qualitative and quantitative analytical methods for charac-
terization of organic contaminants in reclaimed water
(Contract NAS9-14548). These methods have been applied to
the analysis of product water from operation of a prototype
VCD unit. The results of these analyses and their implica-
tions in the light of potential health hazards are discussed
in this report.
2.0 SCOPE
The scope of this effort was two-fold:	 (1) to define
a protocol by which comprehensive reclaimed water potability/
palatability criteria can be established and updated; and
ILI
..........
	
.
NAS9-15368
	 -3-
(2) to continue the effort initiated under Contract NAS9-14548
to characterize the organic content of reclaimed water in the
Regenerative Life Support Evaluation (RLSE).
3.0 OBJECTIVES
3.1 The general objective of the study effort was the develop-
ment of a protocol leading to the formulation of Reuse Water
Quality Standards for aerospace applications that will qualify
the water for human consumption, with particular emphasis on
trace organic contaminants and their potential toxicological
significance.
3.2 The objective of the organic constituent characterization
was to identify and quantify potentially toxic and adverse
taste producing organic components in reclaimed water for the
RLSE program to include the development and demonstration of
analytical procedures
4.0 SPECIFIC TASKS
4.1 Protocol Study
The following tasks were identified in order to accomplish
the first stated objective:
4.1.1 Perform a comprehensive	 literature search.
4.1.2 Identify regulatory roles,	 if any, of other government
entities.
4.1.3 Examine the total concept of reclaimed water in general,
including identification of other potential users of reuse
water outside of NASA and consider possible cooperative programs.
4.1.4 Evaluate current information on the identification and
toxicology of contaminants in spacecraft water supplies.
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4.1.5 Formulate a plan to obtain the necessary toxicological
support information leading to the
z
	 qualification of any
potential recycle system.
4.1.6 Define the specific approach for generation of water
quality criteria to serve as the basis for water quality
standards.
4.1.7 Define an approach for developing Reuse Water Quality
Standards based on adopted water quality criteria that will
allow qualification of any potential spacecraft water source.
4.1.8 Define the appropriate steps which lead from initial
recommended Reuse Water Quality Standards to official accept-
ance and/or approval.
4.1.9 Formulate a schedule and provide a cost estimate for
the total program effort recommended as a result of this
program plan development.
4.2 Organic Constituent Identification/Quantification
The following tasks were identified in order to accomplish
the second objective:
4.2.1 Develop a sampling plan and procedures consistent with
other objectives and the overall objective of the RLSE testing
program.
4.2.2 Perform qualitative analyses of organics in product
water samples at the ppb level with a gas chromatogram-mass-
spectrometer-data system (GC-MS-DS).
4.2.3 Perform quantitative analyses of the carbonaceous matter
in the product water samples (total organic carbon, dissolved
organic carbon, and particulate organic carbon).
NAS9-15368	
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4.2.4 Perform quantitative organic analyses of specific
chemical constituents which present potential toxicity/
potability/palatability problems.
4.2.5 Assist in evaluation of RLSE performance.
4.2.6 Identify potential toxic hazards and a program of
toxicological studies if necessary.
4.2.7 Define spacecraft monitoring requirements for potability/
palatability.
4.2.8 Revise as appropriate preliminary spacecraft potable
water criteria and specification developed under NAS9-14548.
4.2.9 Investigate. the potential formation of iodomethanes
following the addition of iodine to VCD product water. 	 Iodine
is to be used as a biocide during spacecraft storage of product
water.
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PART II: PROTOCOL STUDY EFFORT
1.0 LITERATURE SEARCH (Task 4.1.1)
Both manual and computer searching was used to obtain
listings of potentially useful reference material. A parti-
cularly significant set of abstracts entitled Selected Water
Resource Abstracts (Office of Water Research and Technology,
Water Resources Scientific Information Center, U.S. Dept. of
the Interior) found in the NASA-JSC library proved to be the
best reference source. These abstracts were manually examined
back to 1969 and more than 250 abstracts evaluated. Of these,
approximately 50 were deemed to be of sufficient significance
to warrant obtaining and evaluating the complete article.
Chemical Abstracts was also examined manually but contained no
references not previously found in the above.
Computer searching of STAR abstracts was accomplished
using the RECON terminal in the NASA-JSC library.	 Instruction
on use of the terminal was provided by the library staff and
then the author was left free to try any and all combinations of
descriptor terms desired. Approximately 16 hours was spent at
the RECON terminal including instruction time. 	 Potentially
significant abstracts were called up on the screen and evaluated.
Articles deemed potentially significant were obtained and
evaluated. About ten (10) new references not found in the
Selected Water Resource Abstracts or Chemical Abstracts were
found using RECON. These references were all government contract
reports.
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All pertinent articles obtained in the literature search
were read and evaluated in detail. The results of the search
are of limited value in that there are very few articles
dealing directly with potable reuse of water. A summary of
the findings in the areas of specific interest to this pro-
ject are given below. References are listed in Appendix I.
1.1 Regulatory role identification (Task 4.1.2)
Federal laws have recently established that the U.S.
Environmental Protection Agency along with their state level
counterparts are responsible for quality criteria of public
potable water supplies. Discussions during personal visits
and telephone conversations with Dr. Joseph Cotruvo and
Dr. Craig Vogt of the EPA Office of Drinking Water in Washington,
D.C. indicate that the EPA will want to assume more than an
advisory role in the generation of spacecraft reclaimed potable
water quality criteria. This advisory role can best be accom-
modated by including one or more prominent EPA scientists on
an Advisory Committee to review the criteria. The EPA Office
of Drinking Water has agreed to provide one of its prominent
scientists to serve on such a committee upon request of the
NASA.
1.2 Other users and possible cooperative programs (Task 4.1.3)
The following have been identified as intended users of
reclaimed water for human consumption in the near future:
1.2.1 The U.S. Army:	 U.S. Army Medical Bioengineering
Research & Development Laboratory
(USAMBRDL)
Ft. Dietrich, MD
Contact:	 James C. Eaton, Jr., Phone (301) 663-8000
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1.2.2 The U.S. Navy: Naval Civil Engineering Laboratory
(USNCEL)
Port Hueneme, CA
Contact: Or. D.B. Chan, Phone (805) 982-4173
1.2.3 U.S. Air Force: U.S. Air Force Civil Engineering Center
Panama City, FL
Contact: Major Chester Pauls, U.S.A.F. Headquarters,
Forrestal Bldg., Washington, DC
Other groups with ongoing research in the area of reuse
water include:
1.2.4 The U.S. EPA Office of Water Planning and Standards
1.2.5 The U.S. EPA Health Effects Research Laboratory
1.2.6 The Water Pollution Control Federation
1.2.7 The American Water Works Association
1.2.8 The Safe Drinking Water Committee of the National
Academy of Sciences
Only the former group (the military) have schedules and
requirements much in common with NASA's interests.
In December, 1977, the USAMBROL issued an RFP to provide
a project management plan for development of direct reuse
water quality criteria for Army and Navy (USNCEL) applications.
The evaluation/award was completed on March 16, 1978, and went
to Culp, Wesner and Culp, Inc. (CWC). We attended the Technical
Transfer meeting given by CWC at USAMBRDL at the conclusion
of their study in September, 1978, to determine if coordination
of the NASA and Army efforts was possible. At this time it
was indicated that (1) potable reuse of reclaimed wastewater by
troops in the field was not contemplated, (2) potable reuse is a
possibility at advanced/remote bases to support military operations
in the field over relatively short periods of time (a few weeks),
tom_.
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and (3) potable reuse may be used instead of desalination and
to supplement inadequate supplies at permanent Navy bases, and
(4) that present plans do not anticipate reclaiming urine and/
or fecal wastes. These requirements are so different from
those required for future NASA needs that any cooperatively
funded effort was not felt to be feasible. 41e do recommend,
however, that NASA remain in contact with USAMBRDL and keep
apprised of their developments.
1.3 Reuse water contaminants and associated toxicity (Task 4.1.4)
There is no data available on contaminants in product
water from recycled human
obtained in NASA studies.
health effects of various
supplies proved useful in
product water contaminant
the toxicity evaluations.
wastes other than that previously
Many references obtained on the
chemicals found in drinking water
evaluating the toxicity of the RLSE
s. These references are given in
2.0 ORGANIC CONSTITUENT IDENTIFICATION AND QUANTITATION
(Tasks 4.2.1 -
2.1 Sampling of the VCD
The originally planned November, 1977 operation of the
VCD unit actually occurred in March, 1978. The unit was
operated from March 8, 1978 to March 20, 1978. Eight 160 cc
volume samples were collected for semi-volatile analysis and
fifteen 10 cc volume samples for volatile organic analysis
(VOA). The collection times, analysis times and handling
history of the samples are summarized in Tables I and II.
All samples were collected in No-Chromix acid cleaned glass
r
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septum-seal vials. Care was taken to eliminate any headspace
losses by ensuring all bottles were completely full. The
vials were sealed with teflon lined silicone rubber septa.
A sample of laboratory distilled water from NASA-JSC was
provided to use as a blank. All samples collected from the
VCD unit were condensates.
2.2 Sample Preparation and Analysis
The samples were maintained at 4 0
 C during storage at
Sunnyvale, shipment to Houston and storage at our laboratory.
The samples were received at Spectrix on March 31, 1918.
Iodine solution (supplied by NASA-JSC) was added to one of each
of the five 10 cc samples received in duplicate and to one
130 cc sample to provide a free iodine concentration of 5 ppm.
Addition was accomplished by microliter syringe through the
septum seal to minimize loss of volatiles. The isolated
samples were incubated at room temperature for 10 days to
simulate spacecraft storage.
All samples were analyzed for volatiles and semivolatiles
according to the scheme which follows:
VCD Condensate
Occ	 260cc
volume	 [volume
Volatile Organic
Analysis (VOA)
	
NPOC-POC
	
Semivolatile Organic
Samples	 Analysis	 Analysis Samples
	
lOcc	 lOcc
olume	 volume	 pH 12 Extraction
	
Iodated	 i	 1	 Non-iodated
	
23 0C Incubation	 I 4 0C Storage	 B/H Extract
	
H 2 Extraction
	
40C Storage I	 I	 Analysis
	
Analysis	 Acid Extract
	Analysis	 Analysis
^A- iv
w t=
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The volatiles were placed onto a Tenax trap using a purge
and trap technique similar to that developed by Zlatkis,
Lichtenstein and Tishbee (Chromatographic, 6:67-70, 1973) later
modified by T.A. Bellar and J.J. Lichtenberg (Journal of AWWA,
739-744, 1974) of the EPA. However, rather than using a com-
mercially available liquid sample concentrator, the water was
purged in an all glass apparatus developed in this laboratory
(Figure 1). (Comparative reproducibilities of the two con-
centrators are shown in Table III at three concentrations for
13 compounds.) The tenax trap was then heat desorbed in a
modified injector port. The effluent gas was cryogenically
trapped on a precolumn then rapidly headed to achieve a plug
injection for GC-MS analysis. The analysis was accomplished
on a 0.2% Carbowax 1500 Carbopack-C.
Three pairs of the 130 cc samples were composited to
provide sufficient sample for pH dependent analysis for semi-
volatile compounds to give detection limits of 1-10 ppb. The
pH was adjusted with 6N NaOH to 11 and a liquid/liquid base/
neutral extraction made with methylene chloride. The extract
was dried and concentrated prior to analysis. This fraction
was then analyzed on a glass column packed with 1% SP-2250
on Supelcoport.
The pH of the base/neutral extracted water was then
adjusted with 6N HC1 to 2, extracted with methylene chloride,
and the extract dried, concentrated and analyzed on a glass
column packed with Tenax GC. Prior to analysis of both
fractions, an internal standard of d10-anthracene was added
to each extract.
NAS9-15368	
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All analyses were performed on a Finnigan 3200-INCOS 2300
gas chromatograph-mass spectrometer computer system (GC-MS-COM).
The scan range of the mass spectrometer was 40-275 amu for the
volatiles and 40-425 amu for the extracts. The scan cycle was
3.0 seconds in both cases. Detection limits were in the range
1-10 ppb (micrograms per liter) depending on the specific com-
ponent. The GC-MS interface is a glass jet separator resulting
in a completely glass or glass-lined sample entry system.
The remaining two 160 cc samples were used for carbon
balance studies. Two 10 cc aliquants were removed from each
bottle for VOA and ultra low level total organic carbon analysis.
The remaining 140 cc was extracted for semivolatile analysis
as described above.
The total organic carbon (TOC) analysis was performed on
a Dohrmann Model DC-54 Ultra Low Level Total Organic Carbon
Analyzer System. The analyzer first purges a 10-50 ml acidified
water sample with helium removing inorganic CO 2 produced by
the acidification and purgeable (volatile) organics (POC).
The CO2 is removed by a scrubber. The POC is converted to
CH 4 by reductive pyrolysis which is then measured by a flame
ionization detector (FID). The purged water is then trans-
ferred to a UV s rradiation cell which oxidizes the nonpurgeable
organic carbon (NPOC) to carbon dioxide. This carbon dioxide
is then purged and passed to the reductive pyrolysis unit for
conversion to methane and measured by the FID to give a value
for NPOC. The POC and NPOC are then added to give a value for
TOC.
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2.3 Results
2.3.1 Volatile Results
Table IV summarizes the results of the volatile analyses.
Figure 2 is a typical VOA chromatogram (see Table III: 3-17-78
0900 for results). Compounds appearing on the EPA list of
priority pollutants (Appendix II) were identified by a reverse
search procedure. The reverse search technique is employed
to answer the question, "Is this specific compound present?"
A positive identification of a priority pollutant is made
when the reverse search technique used in this method meets
the following criteria:
(1) The appropriate masses maximize simultaneously;
(2) The retention time is within specified limits; and
(3) The ratio of the masses is correct.
Peaks in the chromatogram not identified by reverse search
were then identified by forward search using the NBS library
and manual interpretation. Response factors were obtained
by analyzing standard mixtures of the seven most prevalent
compounds (1,4-dioxane, dichloromethane, methyl isopropenoate,
benzene, chloroform, hexane, and toluene) at concentrations
of 8, 80 and 240 u g /L. These seven compounds were quantitated
using the authentic response factors which were essentially
linear over the concentration range found here. The remaining
compounds were quantitated using the response of chloroform.
A blank space in the table indicates the compounds were not
detected. Detection limits for the compounds are indicated
at the bottom of Table IV.
NAS9-15368
	 -14-
2.3.2 Discussion of Volatile Results
These results for methyl iodide are very inconsistent
and have no correlation to the laboratory iodation of the
samples. After completing these analyses it was learned
that pretreated urine feedstock containing iodide was used
in the VCD tests. The randomness of the appearance of the
methyl iodide is apparently related to the operation of
the VCD unit.	 It would appear that iodation is not a signif-
icant factor upon product water since all laboratory iodated
samples did not contain methyl iodide. We cannot see any
definite trends in the results of the other volatiles that
correlate with our knowledge of the operation of the unit
or with sample handling and storage. There seems to be no
significant difference in samples stored for long periods
as compared to shorter storage. One notices rather large
differences for quantitative results of dioxane, methyl
acrylate and carbon disulfide for two samples collected only
a few hours apart. Reproducibilities of samples collected
at identical times (3-14-78, 3-17-78 and 3-20-78) are good
indicating the above noted differences are real and are probably
indicative of operational characteristics of the VCD.
2.3.3 Semivolatile Extract Results
No detectable semivolatile compounds could be found in
any of the extracts with a detection limit of 10-100 ug/L
(ppb). Typical chromatograms of an acid and base/neutral
extract are given in Figures 3 and 4. The detection limit
for plasticizers was higher (100 ppb) due to contamination
L.
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of the extracts by the lid liners used in the extract storage
vials. These lid liners are EPA approved, but have recently
been shown in our laboratory to badly contaminate the samples.
It is also possible that these plasticizers were leached from
the plastic tubing known to be used in the VCD unit, but the
lid contamination makes it impossible to pinpoint the source.
The extract data was reversed searched for all the compounds
on the EPA priority pollutant list (see Appendix II) with the
only positive results being those for the phthalate plasticizers.
Table V gives the results of these searches. All peaks were
identified by the reverse search so no forward searches were
conducted.
2.3.4 Carbon Balance
Carbon balance results for the two samples checked are
given below:
Sample	 Total
No.	 POC	 NPOC	 Total Volatiles	 Semivolatiles
1	 61 ug/L	 20 mg/L	 350 ug/L	 Indeterminate
2	 <50 ug/L	 18 mg/L	 34 ug/L	 Indeterminate
Unfortunately the cap contamination problem makes it impossible
to complete the carbon balance.
The intent of a carbon balance study is to account for all
measurable TOC when totaling quantities of individual compo-
nents quantified.
	 Precision of the analyses of volatiles and
semivolatiles as described herein is such that one should be
able to account for 70 - 80% of the TOC if the analyses per-
formed will "see" all the organic material. 	 Organic material
il
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not seen by these analyses could include nonvolatile, non-gas
chromatographable high molecular weight organic compounds and
particulate carbon (charcoal or graphite, for example). Addi-
tional work should be done to achieve this carbon balance on
subsequent VCD samples. Failure to account for the TOC by
volatile and semivolatile analyses after correction for any
particulate organic carbon would indicate the need for high
pressure liquid chromatographic (HPLC) analyses.
NAS9-15368	
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3.0 TOXICITY OF CONTAMINANTS FOUND IN VCD PRODUCT WATER
SAMPLES	 Task 4.2.6)
The purpose of this task was to assess the adequacy of
the data base regarding the toxicity and hazard potential of
the contaminants found in the protot ype VCD ;eater reclamation
system product water. An intensive search of the available
published literature was conducted in regard to each of the
15 compounds identified by chemical analyses of the submitted
samples.
Both computer-assisted and direct search of chemical
abstracts and Index Medicus were conducted within the library
system of the U.T. Health Science Center. Data referral systems
such as RTELS, TOXLINE, TOXBACK and CANCERLIT were also searched
using appropriate proper names of the compounds and their syn-
onyms. Further, standard texts and current periodicals were
screened for relevant documentation.
Primary attention was addressed to physiological and
biochemical studies that utilized mammalian species, including
man.	 Included in the review were references dealing with the
metabolic fate, acute and chronic toxicity, and any confirmed
evidence of carcinogenicity, teratogenicity or embryo toxicity.
Available material for each compound was compiled and summarized.
This information as well as a recommendation for an interim
drinking water standard, where data permit, is presented in
Appendix II,I.
4.0 REVISION OF PRELIMINARY SPACECRAFT POTABILITY/PALATABILITY
C	 as
For 12 of the compounds there were adequate toxicity and
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hazard assessment data available to make a judgment regarding
an interim drinking water standard. These are incorporated
into Table IV which is an updated suggested reclaimed potable
water quality specification which includes all potability/
palatability factors. There was sufficient information to
assure little or no hazard to the proposed population at con-
centrations at or below the levels recommended.
It should be noted that the recommended concentrations
are not intended to provide a uniform safety factor. In each
case the recommendation was a subjective judgment based on all
the available knowledge of and the nature of the health risk.
The metabolic fate, the acute and chronic toxicity and the
potential for irreversible damage were all considered in
making a judgment. It was also assumed that water consumption
would not exceed 2 liters per person per day. We recognize
this figure may be low since it does not include water for
food reconstitution which should be included when future
missions are better defined. No consideration was given to
acceptability of the recycled water in regard to either smell
or taste. Health considerations alone dictated the judgment.
In several cases, the standard might have been relaxed
if financial considerations were an important factor. We
considered, however, that consistent with the available
technology, a conservative interim standard would best protect
the population to be exposed.
For the remaining three compounds:
1,2-Dithiol ethane
2-methyl furan
methyl acrylate
14
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there were essentially no data upon which to base any judg-
ment regarding a drinking water standard. In regard to these
compounds, there appear to be two courses of action:
(1) Eliminate the source of these materials from the
system; or
(2) Develop an adequate data base upon which to make
an appropriate judgment.
5.0 HEALTH EFFECTS RESEARCH REQUIREMENTS (Task 4.1.5)
Many health considerations should be included in a manage-
ment plan for establishing Reuse Potable Water Quality Criteria.
However, the U.S. domestic drinking water criteria are of little
value in regard to this program since:
(1) this program is primarily concerned with organic
compounds whereas the U.S. domestic program has
only limited activity in this area; and
(2) there is no assurance that the carbon chloroform
extract (CCE) method is adequate for monitoring all
organic compounds of toxicological interest. The
CCE standard was developed as a test for undesirable
tastes and odors in drinking water, not for identi-
fying or quantifying toxic trace organics.
Considerations that have not been adequately addressed
include the following:
. (1) No one knows, nor is there any satisfactory method
of predicting the type or quantity of contaminants
produced from multiple re-cycling of physiological
system by-products;
. NAS9-15368
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(2) There is little or nothing known regarding the
potential for harmful effects from mixtures of
either the compounds already identified or those
potentially present in a re-cycle system;
(3) There is no way of predicting the impact of pro-
phylactic or therapeutic drugs or their biochemi-
cal transformation products in any re-cycle water
system;
(4) In systems where both sexes would contribute by-
products, it is impossible to predict the health
consequences of various excreted endocrine materials
or their biotransformation products in addition to
any or all of the above.
The only satisfactory way to address the above consider-
ations is by way of an appropriate bioassay procedure.
We propose the following investigation to address the
above considerations.
(1) Isolate separate groups of male and female rats in
metabolic units that are capable of collecting all
water from physiological processes, including the
expired air.
(2) Maintain these groups of animals on their own re-
cycled water for a one-half life period (1 year).
This would permit 50 cycles of water through the
animals. The recycling system can be the actual
prototype hardware or a laboratory simulator using
the same purification principles.
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(3) Identical, but separate groups of animals would
receive, in addition to the above, various drugs
that would find use in a spacecraft mission.
(4) All animals would be maintained for a second year
under normal laboratory conditions, then sacrificed
to assess any potential for either chronic toxicity
or cancer as compared to concurrent control animals.
(5) Evaluate present analytical methods to verify that the
detection limits for drugs and endocrine materials (e.g.,
hormones) are sufficient to meet toxicity requirements.
(6) Chemical analyses would be conducted on each cycle
of re-cycled water to evaluate any change in compo-
sition of the system contaminants.
(7) An Ames test assay would be conducted on a sample
at each re-cycle to predict the development of any
mutagenic potential in each system.
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PART III: RECOMMENDED PROTOCOL FOR ESTABLISHING POTABLE REUSE
WATER QUALITY CRITERIA FOR MANNED SPACEFLIGHT
(Tasks 4.1.6 thru 4.1.9)
1.0 REVIEW COMMITTEE
We recommend that NASA establish a five person review
committee of nationally recognized experts to consider, review
and approve water quality standards for potable reuse of
reclaimed water in manned spaceflight. Experts in the following
scientific and/or engineering disciplines should be included:
(1) Carcinology;
(2) General toxicology;
(3) Aerospace medicine;
(4) Mutagenicity or virology; and
(5) Water quality.
Members of the committee should be chosen so that they may
also serve as official representatives of the National Academy
of Sciences, the Environmental Protection Agency and the
National Association of American Toxicologists. Although these
groups have no mandate requiring their involvement in establish-
ing NASA water standards, their acceptance or approval will be
very beneficial. We estimate that this committee will meet
quarterly to hear briefings on progress of standards develop-
ment and to provide feed back to serve as guidelines to future
action.
2.0 TASK GROUP
We recommend that a tt. 'e person Task Group be established
to support the Review Committee. This Task Group should be
t NAS9-15368
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composed of experts in the fields of general toxicology, ana-
lytical water chemistry, and spacecraft engineering. We
estimate that up to twenty-five percent of full-time will be
required for the Task Group members to properly support this
effort. Supporting Task Group staff services including
secretarial work, technical editing, library services, graphic
services, and the mechanical production of Task Group reports
will be required.
The assignment of the Task Group will be to develop water
quality criteria for potable reuse of reclaimed wastewaters in
manned spaceflight for presentation to the Review Committee.
The water quality criteria should take the form of maximum
allowable levels of contaminants based on health aspects and
minimum amounts of any chemicals necessary to maintain suitable
palatability.	 Specific assignments should include, but not
be limited to, the following tasks.
2.1 Identification of Systems to be Qualified
At the present time NASA is considering only the VCD
reclamation system for future spaceflight. Development of
water quality criteria will necessarily be directed more to
the peculiar characteristics of this type of system, but care
should be taken to insure that the criteria can be applied to
any new systems developed in the future.
2.2 Development of a Plan for any Research Effort Required
Previous NASA efforts (Contracts NAS9-14548, NAS9-12969
and NAS9-15368) have shown that additional research is needed
to develop analytical methods to completely characterize the
MIR
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organic contamination present in prototype VCD unit product
water and to determine the toxic potential of these contami-
nants under exposure conditions in long term spaceflight.
In particular, only 10-25 percent of the total organic carbon
(TOO found in the water has been accounted for in individual
component analyses. It shall be the duty of the Task Group
to evaluate the existing data and recommend further research
in ana'iytical toxicology, microbiology, and health effects
which may be required to provide an aedquate basis for setting
water quality criteria regarding health aspects. NASA must
then fund the required research.
2.3 Palatability Requirements
The removal of essentially all inorganic cations and anions
accomplished by the VCD reclamation system results in an essen-
tially tasteless water. This tastelessness could adversely
affect astronaut water consumption. NASA experience has shown
that it is important that astronauts consume sufficient water
to prevent partial dehydration. Previous efforts (NAS9-12969)
have identified ingredients which can be added to the VCD
product water to enhance the taste and encourage normal con-
sumption. The Task Group shall evaluate this data for inclusion
in the water quality criteria.
2.4 Flight Qualification Test Plan
Flight qualification is required for all systems to be
flown in spacecraft. The qualification test plan usually
requires submitting the equipment to environmental testing
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simulating extremes of expected Flight environments such as
gravitational, thermal, mechanical, etc., for time periods
that will insure it does not fail during expected flight
durations of these environments. The questions of how long
one should test a piece of equipment that is supposed to
produce a consummable product within rigid specifications for
extended periods of time has not normally been addressed in
flight hardware test plans.	 It shall be the duty of the
Task Group to develop a suitable flight qualification test
plan to insure production of potable water for established
flight durations. This plan should be based on operational
history of prototype flight equipment insofar as available
and shall specify what parameters must be monitored to
assure adequate water quality during the flight testing.
The fact that no alternate water supply will be available
during flight may be a Key fac^or here.
2.5 Flight Monitoring Requirements
The question of in-flight monitoring requirements must
be considered in developing the water quality criteria.
Health effects research on expected contaminants may indicate
the need for non-conventional monitoring which is not presently
available.	 It shall be the duty of the Task Group to identify
these requirements as soon as possible so that any necessary
development of monitoring devices may be accomplished in
time to meet projected flight schedules.
W.
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2.6 Interim Standards
Interim water quality standards may be required to meet
design and testing dates prior to development of final water
quality criteria.	 It shall be the duty of the Task Group to
identify the need for and recommend Interim Standards to the
Review Committee for their approval.
3.0 ORGANIZATION OF THE WATER QUALITY CRITERIA DEVELOPMENT
EFFORT
We recommend that the development effort be organized as
indicated below:
NASA Johnson
Spacecraft Center
Development
Contractor
Review
	 Project
	
Task
	
Committee '-'-- Director
	
Group
Consultants
I
Supporting I
Services Group f
NASA-JSC should select a Contractor to carry out the effort
required to establish approved water quality criteria. This
effort can then be carried out under a Project Director. The
Project Director shall organize the Review Committee and the
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Task Group and arrange consulting contracts between the members
and the Development Contractor to cover their time and travel
expenses. Review Committee members employed by other government
agencies may be covered for their consulting time through inter-
agency agreements. Final approval of Review Committee members
should be subject to NASA Headquarters approval.
The Project Director shall define, direct, and coordinate
the efforts of the Task Group and serve as the interface between
the Task.Group and the Review Committee. The Project Director
shall be responsible for calling Review Committee meetings,
establishing the agenda, and insuring Review Committee recommen.
da tions are reflected in subsequent Task Group efforts.
The Supporting Services group shall provide secretarial,
reproduction, graphics and technical services as requested by
the Project Director to support the Review Committee and Task
Group Functions.
4.0 SCHEDULE FOR ESTABLISHING APPROVED CRITERIA
An estimated schedule which lists the major tasks and
milestones is shown in the enclosed chart.
5.0	 COST ESTIMATES
Estimated costs for the proposed four year program are
as follows:
5.1 Professional Labor and Overhead 	 $318,400
(1) Project Director (1 man year) $115,000
(2) Secretarial (1 man year) 	 $ 21,600
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(3) Other nonprofessional labor
(2 man years)
(4) Review Committee Consulting
Fees
60 days @ $500/day
(5) Task Group Consultants
360 days @ $250/day*
$ 55,800
$ 30,000
90,000
*Assumes Spacecraft Engineer is a
NASA employee
5.2 Contract Research Effort for Toxicity
	 $500,000
Studies
Total Estimated Cost	 $818,400
NAS9-15368
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EPA PRIORITY POLLUTANTS
EPA PRIORITY POLLUTANTS
COMPOUND
acenaphthene
acrolein
acrylonitri le
A W
NO. 1
	
COMPOUND
3.1A 2,4-di chlorophenol
32V 1;2-dichloropropane
33V 1,3-dichloropropylene
benzene	 '34A 2,4-dimethylphenol
benzidine
	 358 2,4-dinitrotoluene
carbon tetrachloride
chlorobenzene
1.2,4-trichlorobenzene
hexachloroben-zene
1.2-dichloroethane
1,1,1-trichloroethane
hexachloroethane
1„1-dichloroethane
1,1,2-trichloroethane
1,1,2,2-tetrachloroethane
chloroethane
bis(ch1oromethyl)ether
bis(2-chloroethyl')ether
2-chloroethylvinyl ether
2-chloronaphthalene
2,4,6-tri chlorophenol
oarachlorometa cresol
chloroform
2;chlorophenol
1,2-dichlorobenzene
1.3-dichlorobenzene
1,4-dichlorobenzene
3.3' -dichlorobenzi dine
1.1-di chl oroethylene
1.2-trans-dichloroethylene
366 2,6-dinitrotoluene
37B 1,2-diphenylhydrazine
38V ethylbenzene
3 98 fl uorinthene
	 -
409 4-chlorophenyl phenyl ether
41B 4-bromophenyl phenyl ether
42B bis(2-chloroisopropyl)ether
438 bis(2-chloroethoxy)methane
44V methylene chloride
45V methyl chloride
46V methyl bromide
47V bromoform
48V dichlorobromomethane
49V trichlorofluoromethane
SOV dichlorodifluoromethane
51V chlorodibromomethane
528 hexachlorobutadiene
538 hexachlorocyclopentadiene
64B isophorone
553 naphthalene
563 nitrobenzene
67A 2-nitrophenol
58A 4-nitro-phenol
69A 2,4-dinitrophenol
60A 4,6-dinitro-o-cresol
As it appearsin "Sam ling and -
 Analysis Procedures for Screening of
Industrial Eff-^ ents or Priority Rol- l-utants,” EPA,—Revised April, 1971
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EPA PRIORITY POLLUTANTS
(Continued)
COMPOUND	 NO.i	 COMPOUND
N-nitrosodimethyl amine	 88V vinyl chloride
N-nitrosodiphenylamine	 89P al drin
N-nitrosodi-n-propylamine 	 90P dieldrin
pentachlorophenol
	
91P chlordane
phenol
	
92P 4,4'-00T
bis(2-ethylhexyl)phthalate 	 93P 4,4'-DOE
butyl benzyl phthalate	 94P 4,4' DDD
di-n-butyl phthalate	 95P a-endosu1fan-Alpha
di -n-octyl phthalate	 96P b-endosulfan-Beta
diethyl phthalate	 97P endosulfan sulfate
dimethyl phthalate	 98P endrin
benzo(a)anthracene	 99P endrin aldehyde
benzo(a)pyrene
	
,COOP heptachlor
3,4-benzofluorathene
	 101P heptachlor epoxide
benzo(k)fluoranthane
	 102P a-BHC-Alpha
chrysene	 103P b-BHC-Beta
acenaphthylene
	 104P r-BHC-Gamma
anthracene
benzo(ghi)perylene
fluorene
phenanthrene
di benzo ( a,h) an thracene
ideno(1,2,3-cd)pyrene
pyrene
tetrachloroethylene
toluene
tri chIo roe thy Iene
105P a-BHC-Delta
106P PCB-1242
107P PCB-1254
108P PCB-1221
109P PCB-1232
11OP PCB-1248
111P PCB-1260
112P PCB-1016
113P toxa hene
129^1,7 8-tetrachloro i benzo-
p-dioxin
it appears in "Sampling and Analysis Procedures for Screening of
ustrial EffiTuents for Prfiort-ty"PoTTu tan ts," EPA-,-
 Revised April .1977.
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ACETONE
Introduction
MOLFM: C3H60 MW: 58.08 d25 0.788
Water Solubility: infinite
SYN:	 dimethylketone, OMK, 2 -propanone, 8-ketopropane
Used as a solvent
Product of normal metabolism resulting in blood levels of 0.3-2.0 mg
per 100 ml.
Literature: relatively sparse; most current listings of toxicity refer
to older studies.
Metabolism
Acetone is fairly rapidly absorbed and distributed among the various
tissues relative to their water content. Acetone is eliminated unchanged
in the expired air and urine as well as metabolized. From equivalent
blood levels (72 mg/1) in the rat and man, it was found that the rate of
disappearance of acetone from the blood was 5.6 mg and 2.2 mg/ kg/hr.
respectively. 1 This same study found that at very high blood levels of
acetone, elimination as unchanged acetone was of more importance in rate
of disappearance but a lower blood levels metabolism may account for more
than half of the acetone lost. The metabolic pathways have been characterized
primarily as a direct oxidation to a 3-carbon intermediate of glycolysis
("pyruvate" formation) and secondarily as acetoacetate and "formate"
production.2
N AS9-15368
Acetone
	
A-2
Acute Effects
Acetone appears to be relatively safe at fairly high concentrations.
Oral doses of 15-20 g/day for several days by human subjects gave no sign
of ill effects other than a slight drowsiness. 3 For rats, the median
concentration of acetone in the jugular vein at loss of rightin g reflex
was 3000 mg/l, at loss of corneal reflex, 5110 mg/l, and at respiratory
failure 9190 mg/1. 1 An eight hour inhalation exposure to slightly over
2000 ppm daily would result in an accumulation of under 350 mg/l of acetone
in the blood, which in turn would give no significant symptoms of exposure. 1,3
The single oral lethal dose for rabbits and dogs has been estimated as
8 g/kg. 4
 For man the estimated minimum lethal oral dose in 50 ml 5
 while
10-20 ml orally may be taken without ill effect.6
Chronic Effects
None reported in available literature.
Carcino enicity/Teratogenicity/Embryotoxicity
None reported in available literature.
Current Standards
The current U.S. TLV is 1000 ppm. 7 No water standard is currently set
for the U.S. One report from Russia recommends a standard of 39.6 mo/l for
3 months and 14.0 mg.l for 1 year in recycled drinking water.8
Recommendations
Acetone appears to be a relatively safe chemical even at very high
levels. However, the lack of recent literature regarding chronic effects
NAS9.15368
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coupled with the conservative Russian standard suggests caution.
We recommend an upper limit of 50 mg.il acetone in drinking water.
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BENZENE
Introduction
MOLFH: C
6 H 6
MW: 78.12
	 d4 5 0.8787
Water solubility: 0.8ppm
SYN:	 Benzol, coal naphtha, phenyl hydride
Used as a solvent and as a starting compound for other chemical
compounds.
Of ten drinking water supplies surveyed by the EPA, four were found
to have concentrations of 0.1-0.3 ua/l.9a
Literature: a large number of studies are available, several excellent
reviews are available 10-16 which basically rifer to
the same body of literature and contain many similar
discussions.
Metabolism
Benzene is readily absorbed by the lungs and once in the bloodstream
is easily concentrated by various organs and tissues especially those
that are lipophilic in character. The concentration in bone marrow many
become 167 fold to 20-fold over that found in the blood. Benzene is
metabolized in the liver primarily to phenol, catechol and quinol and
secondarily to hydorxy quinol. Benzene may be excreted in the expired
air as unchanged benzene or in the urine as unchanged benzene, free
metabolites or metabolites con,jungated wiO glucuronic or sulfuric
acids. With the exception of the cat and the pig, 17 species follow this
same general pattern of metabolism.
aNAS9-15368
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Acute Effects
These effects are well documented and range from euphoria to loss of
consciousness to death. These effects occur at concentrations rruch
greater than will ever be found in recycled water and will not be discussed
in detail at this time.
Chronic Effects
Chronic effects are harder to document. Most exposures are by the
inhalation route and are thus hard to extrapolate to the oral route. In
one study, mice exposed to 100 ppm benzene for 5 days showed a decrease
in wheelturning activity as well as a definite degenerative change in the
bone marrow whereas mice exposed to 10 ppm showed no change in wheelturning
activity and only a slight degenerative change in bone marrow. Rats
exposed to 20 ppm for 5.5 months showed a decreased response time to a
conditioned reflex whereas rats exposed to 4 ppm showed no change. Pats
exposed to 10 mg/kg orally for 132 days showed signs of leukopenia. An
in vitro using cultured human leukocytes and 1.1 X 10 -3 M benzene resulted
in chromosomal gaps and breaks in a 72 hr. culture.
Chronic effects in humans are harder to relate to a definite exposure.
Many studies include industrial exposure and concentrations are hard to
document completely.
Mechanism of Action
Chronic benzene toxicity seems to be related to the levels and amounts
of benzene metabolites in the test subject. It has been observed, however,
i ---
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that inducers of metabolism will reduce toxicity perhaps by resulting
in earlier secretion before the benzene starts accumulating in the bone
marrow. Inhibitors of metabolism at times will reduce toxicity. Three
general hypotheses regarding chronic benzene toxicity are:
1. The phenolic intermediates may produce chromosomal aberrations
or reduce mitotic rates.
2. Depletion of glutathione in the bone marrow may subsequently
interfere with redox reactions leading to bone marrow depression.
3. The immune surveillance system may be affected allowing the
proliferation of cell types normally destroyed.
Problems of Prior Studies
Some of the important points to consider in the evaluation of most
of the studes are:
1. Liver metabolism is the primary site of study but the toxic
action of interest occurs in the bone marrow.
2. Despite deplication of some of the human blood disorders in
animals, there is at present no good animal model for the major
toxic affect of interest.
3. There may be a strong interplay of unique genetic sensitivity
and other chemical, physicial or viral agents.
4. Lack of mutagenicity in the Ames test.
5. Lack of embryotoxic and teratogenic data.
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Current Standards
The NIOSH (1974) recommended 8 hr. TWA is 10 ppm 
17 
No water
standard has been recommend for the U.S. 9a
Recommendations
Current fears that benzene may be a human carcinogen dictates that
exposures be maintained at a relatively low level. We recommend an
interum standard of 0.1 mg/l benzene in drinking water.
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CARBON DISULFIDE
Introduction
MOLFM: CS2 MW: 76.14 d4 1.293
Water Solubility: 0.294%
Syn:	 carbon bisulfide, dithiocarbonic anhydride.
Used in various manufacturing processes including the rayon, rubber,
solvent and pesticide industries.
Detected in 5 out of 10 drinking water supplies. 9b
Literature: a large number of studies are available but these deal
primarily with occupational studies in the viscous rayon
industry or inhalation studies with test animals.
Metabolism
Following an 8 hour expusure, rat blood levels of CS 2 rapidly declined
within 7 hours primarily by pulmonary excretion. Some of the inhaled CS2
was metabolized to nonvolatile, S-containino compounds which showed
prolonged retention with respect to free CS 2 . CS 2 is postulated to react
with endogenous amines or thiols to form dithiocarbamates or trichio-
carbonates which may be responsible for subsequent tissue damage. One
third of acid-labile CS2 in brain tissue was still present 16 hours after
exposure was stopped. 
18 
Other investigators have shown metabolism and
excretion to CO 2 ;
19
 and trace amounts of thiourea and thiazolidine.20
A single oral dose of CS2 inhibited MFO enzymes in rat liver microsomes.
Other studies have confirmed depression of MFO activity and cytochrome
P-450 levels. Cytochrome P-450 levels can be increased to similar levels
V
both by phenobarbitone pretreatment and starvation, however, the CS 2 -
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induced damage occurs only in the phenobarbitone-pretreated group suggesting
that a MFO - Metabolite may not be responsible for the damage seen.2
Acute Effects
Acute exposure to CS  can result in euphoria, restlessness, nausea,
vomiting, unconsciousness and terminal convulsions,
Chronic Effects
These effects are primarily the result of worker exposure in the
viscous rayon industry. 28 This exposure may tend to stay stable at certain
concentrations with intermittent peaks. However, various areas within
a plant are often characterized by different levels allowing for relative
comparisons, Many of the effects of concern deal with nervous system
parameters including polyneuritis, difficulty in walking, vertigo, tremors,
various psychoses, dimentia and decrease in nerve conduction velocity.
There are also strong indications of increases in coronary heart disease
and dysfunction of male and female reproductive systems. Animal data
primarily supports or adds to observations made in humans. Other studies
have indicated an increased tendency to hemolysis after exposure to CS 
resulting from disruption of key enzymes in the glycolytic cycle and
decrease in ATP levels, 
22 
continued diene conjugation of liver phospholipids
after other parameters returned to normal values during subacute exposure23
potentiation by aminotriazole24 and phenobarbitone with preferential
binding of sulfur rather than carbon in the brain 25 and a "dyina back"
neuropathy similar to that induced by acrylamide.26
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Carcinogenicity/Mutagenicity/Teratogenicity
Teratologic/embryotoxic effects have been observed in a least two
studies. 
96 
A recent stud_v27 exposing pregnant Wistar rats to 50,100 and
200 mg/m3 throughout gestation showed dose-related, detrimental effects
on F1 progeny. Mating within the F 1 progeny without further exposure to
CS2 resulted in similar structural abnormalities in the F 2 generation
for the groups exposed to 100 and 200 mg/m3.
Current Standards
28
The U.S. occupational standard is set at 3 mg1t1 3 ,	 and the Russian
occupational standard is 10 mg/M3. 96 However, it should be noted that
another study of CS  exposure of 0.1 mg/M 3 for 6 months with rats showed
a 16% increase in blood cholinesterase activity 
29 
and that workers exposed
to 10 mg CS2/M3 , the current Soviet maximum permissible concentration,
developed ? number of pathological conditions. 
30 
The National
Research Council (1977) 96
 has taken the position that not enough is known
about CS  to set a water standard at this time.
Recommendations
Carbon disulfide is a difficult compound to evaluate. Most of the
literature deals with inhalation studies and a large part deals with
epidemiological data that is difficult to quantify accurately. The
effects of CS  appear to be cumulative especially in the case of neuropathy
indicating a need for conservative action. We recommend an interim
standard of 0.05 mg/1 carbon disulfide in drinking water, but suggest further
investigations be started to resolve the problem of ccmmulative effects.
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CHLOROFORM
Introduction
MOLFM: CHC1 3	MW 119.31 d20	1.484
Water solubility: 0.51.
Sy":	 trichloromethane
Used as a refrigerant, aerosol propellant, various manufacturing
processes and in extraction procedures. Found in almost all finished
drinking water supplies (mean concentration 20 ug/ 1 ) as a result of
the chlorination process.. 9c
Literature: a large number of publications are available.
Metabolism
Chloroform is apparently rapidly absorbed, distributed and excreted in
mice, rats and humans. A single oral dosing in man resulted in 40°; expired
unchanged and 50.00 expired at CO 2 within 8 hours. 
31 
Early literature showed
that an unknown metabolite was responsible for observed affects. 32,33
This metabolite was later shown to depend upon a C-450 dependent oxidative
pathway, 
34,35 
and to be phosgene. 36, 37
Acute Effects
Acute effects are characterized by liver enlargement, he patic and renal
lesions and necrosis. These all occur at much higher concentrations
than those observed in drinking water.
Chronic Effects
One clinical trial 38 for 1-5 years with an estimated daily oral dose
A-12
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of 0.3-0.96 mg/kg showed no signs of h,,:patotoxicity whereas another trial39
with estimated daily oral doses of 23-37 mg/kg resulted in some reversible
hepatoxicity. Several animal studies have shown chloroform to be a
carcinogen. 40,41 Using dose-response techniques of extrapolation, the
95% upper confidence estimate of lifetime cancer risk per mg/i/day has
been calculated as 1.7 x 10
-6 and has been "remarkably consistent" from
the individual data sets used. 9C The NCI data sets have been confirmed
using the same strains and similar doses. 42
Carcinogenicity/Mutagenicity/Teratogenicity
A teratology study in rabbits showed fetotoxicity in terms of reduced
birth weights at the higher doses but no evidence of teratogenicity
looking at external, skeletal and/or soft tissue abnormalities. 43
However, this study does not evaluate the possibility of potential
decreased learning ability in the offspring.
Interactions
Pretreatment with metabolic inducers such as phenobarbital and chloro-
promazine has been shown to potentiate glutathione decrease and liver
necrosis following chloroform challenge 23 whereas metabolic inhibitors
such as SO 525A, piperonyl butoxide or CS 2 have been shown to antagonize
subsequent chloroform challenge 44	 Chloroform induced hepatotoxicity in
mice has been shown to have a strong genetic basis and to be potentiated
by testosterone levels in both males and females. 45
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In Vitro Studies
Lack of mutagenicity was shown when cultured Chinese hamster lung
fibroblast cells were exposed to 1-3a chloroform for one hour and the
bottle sealed for a total of 24 hours. 
46 
However, it is questionable
whether or not the same microsomal oxidation occurred in these lung cells
that occurs in liver cells and is responsible for the production of the
toxic metabolite.
Current Standards
A total haloform concentration of 70 ug/l has been referred to as
"reasonable" in a report referencing both animal studies and epidemiological
information. 47 The interim primary drinking water standard for total
trihalomethanes has been set at 100 jig/l. 43 Due to its carcinogenic
properties, chloroform was banned from human druns or cosmetics in 1976.49
A ceiling limit of 2ppm for 1 hr has been recommended for occupational
exposures. 50
Recommendations
The number of studies confirming the potential for chloroform-induced
carcinogenesis, the "remarkably consistent" extrapolation of animal data
to low doses, and the potential for potentiation by metabolic inducers,
supports the need for a strict chloroform standard in drinking water.
The Interim Primary Drinking Water Standard for total halomethanes of 0.1 mq/1
seems reasonable at this time. Since chloroform represents the major portion
of total halomethanes, we recommend a standard of 0.1 mg/l chloroform in
drinking water.
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Introduction
MOLFM: C4
 H8
 02	MW;88.10	 d20 1.0329
Winter solubility: 00
Syn: 1,4 - dioxane, p-dioxane, diethylene dioxide
Used as a solvent in many applications
Literature: many published papers available
Metabolism
In an inhalation study of dioxane in human subjects, it was found that
a concentration of 50 ppm for a six hour exposure period resulted in a
total absored dose of 5.4 + 1.1 mg/kg. 51 This study also revealed that
dioxane has a half-life of 59 + 7min. at 50 ppm exposure is excreted
primarily as betahydroxyethxyacetic acid in the urine. This metabolite
may also be referred to as p-dioxane -2-one as the two are interchangeable
forms depending forms depending upon the pH of the solution. 52
 Young,
et. al. 
51 
concluded that 50 ppm in the air would produce no accumulation.
The metabolic disposition of dioxane does show saturation 
53 (thus no
alternate pathway) and induction by metabolic inducers 52,54,55 or hioh
doses of itself. There are indications that the toxic compound may
actually be a further metabolite of p-dioxane-2-one.55
Acute Effects
Studies indicate that acute toxicity of dioxane is associated with
necrosis of the kidney renal cortex and liver centrilobular area as well
as edematous lungs and brain. 56
NAS9 . 16%Z 68
A-15
Dioxane
Chronic Effects/Carcinogenicity
Many chronic studies have been done exposing different test species
to different dioxane concentrations for different time periods, 57-.60
Most of the observed effects occur at l; or higher concentrations in
drinking water and include increased number of tumors in nasal cavities,
liver and kidney.
	
In the liver and kidney , the tumors seem to have a
strong association with signs of necrosis and tissue hyperplasia whereas
a concentration of 0.01% (9.6 and 19.0 mg/kg/day for male and female
rats . respectively) for 2 years showed no effect. In general, the data
support a dose-response relationship.	 Another study using detailed
electron microscopy documents progressive tissue changes with total oral
dose received over time. 61
Mutagencity/Teratogenicit
None reported in available literature..
Current Standards
The current NIOSH air standard is 1 ppm. 56 There is no drinking
water standard.
Recommendations
Although dioxane has carcinogenic potential, it seems to be strongly
associated with prior tissue necrosis. This observation from several reports
along with differences in pharmacodynamic parameters from high to low doses
has lead Watanabe et. al, 
62 
to argue against extrapolation of dioxane
data to very low doses.
We consider that 1 mg/l dioxane in drinking water will provide adequate
protection from recognized hazard.
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ETHANE, 1121DITHIOL
Introduction
MOLFM: C2H6S2 MW 94,2	 d23,5 1,123
Solubility: relatively insoluble in water
Syn:	 Dithioethyleneglycol, ethylenedimercaptan t dimethyl sulfide
dimethyl disulfide
Literature: there is little available literature on the toxic effects
of 1,2-dithiolethanet
Metabolism
No studies noted in available literature.
Acute Effects
The Merck Index63
 warns that vapors may cause severe headaches and
nausea. The RegistrX of Toxic Effects 64 lists a single reference giving
the subcutaneous LD50 in mice as 100 mg/kg.
Chronic Effects
No studies noted in available literature
Current Standards
None noted.
Rec anmendations
No data exist on which to establish a standard.
:E
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ETHANE, 1,1,1-TRICHLORO-
Introduction
MOLFM: C2 H3 C1 3	MW: 133140	
d220	
1.3316
Solubility: relatively insoluble in water
Syn:	 Methyl Chloroform, TCEA
Used as a solvent,
Metabolism
An inhalation exposure to rats of 204 ppm for an 8 hr, day, 5-day
week for 14 weeks showed that most of the 1,1,1-trichloroethane (TCEA)
is excreted via the lungs as unchanged TCEA, 65 an ip. dose of 700 mg/kg
resulted in 98.1% of the TCEA excreted unchanged via the lungs in 25 hours., 66
Another 0.5% was excreted as CO 2 while most of the rest was excreted as
the glucuronide of 2,2,2-trichloroethane in the urine. The exact rate
of elimination is in apparent dispute with one author arguing for first
order uptake and elimination 67 and another for exponential decay with time.. 68
Both seem to agree however, that there is a strong relationship between
concentration of exposure and length of time of exposure with organ con-
centrations ten times higher for a total exposure administrated at a high
dose and short time period compared to a low dose and a lengthy exposure.
In general, there appears to be no accumulation in tissue. TCEA does appear
to induce the mixed-function oxidase system. 69
Acute Effects
TCEA acts as an anesthetic with only a slight capacity for liver damage
although some liver stress is produced. 
68 
TCEA does not appear to enhance
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triglyceride levels, increase diene conjugates or decrease glucose
-6-phosphatase activity. 67 TCEA seems to act on the electron transport
chain 
70 
and results in peripheral vasodilation followed by depression of
myocardial function. Acute exposure also potentiates epinephrine-induced
cardiac arrythmia.71
Chronic Effects
Exposure of dogs, mice, rats and monkeys continuously for 90 days at
250 ppm produced no significant deleterious findings. 72 Workers exposed
to an estimated TWA of 115 ppm TCEA 8 hrs/day, 5 days/week for up to five
years showed no adverse effects. 73
Mutagenicity/Carcinogenicity
No mutagenic effects have been noted using the Ames test system with
and without induced rat liver microsomes. 75 However. these same authors
failed to show effects with carbon tetrachloride and methylene dichloride.
A recent carcinogenesis assay 76 failed to show carcinogenic activity in
both mice and rats as the controls had similar neoplasms and the treated
animals had abbreviated life spans. In contrast. TCEA wa shown to affect
transforming acttvity of Fisher rat embryo cells as measured by relative
plating efficiency at a concentration as low as 9.9x10-1 um thus showing
more activity than trichloroethylene.77
Current Standards
The recommended NIOSH standard has a TWA of 350 ppm. 74
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Recommendations
Most studies of 1,1,1-trichloroethane show it to be a relatively
inoccuous compound even when inhaled at very high levels. However, at
this time there do not appear to be any good ingestion studies upon which
to base a drinking water standard. We recommend an interim standard of
1 mg/kg TCEA in drinking water.
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FURAN, 2-METHYL-
Introduction
MOLFM: C 5 H6 0
	
MW: 82,11	
d220	
0;9132
Solubility: relatively insoluble in water
Syn:	 Silvan
3-methyl furan has been found in rainwater samples during an
atmospheric smog alert, 78
Literature: very little literature was noted on 2-methyl furan
but there are many articles on furan analogues that
suggest that the furan ring is of primary importance
in their toxicity. These generalities are discussed below.
Metabolism
Most studies suggest metabolic activation of the furan ring possibly
by epoxidation followed by covalent binding to a target site. This
activity requires molecular oxygen and a NAOPH generating system. 79-84
The damage has been prevented by piperonyl butoxide administration. 82
Effects of Furan-Containing Analogues
The oral LO 50 and inhalation LO low for 2-methyl furan in the rat
have been reported as 167 mg/kg and 377 ppm/4H respectively. 64 The
double bond in the terminal furan ring of aflatoxins and analogs was
found to be important to the potency of these compounds in both acute
and chronic effects. 21183
 It has been found that 0.23 nnol/liter air for
1 hr, or 100-200 mg/kg ip. dosages
damage to lung bronchiolar cells82
cells.
80
 Studies with 2-(N-ethyl
ip. showed damage primarily to the
of 3-methyl furan could result in
or more specifically, the Clara
:arbamoylhydroxymethyl) furan injected
lung and secondarily to the liver. 34
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This damage was associated with covalent binding via the furan ring.
Studies of furosemide metabolism, distribution and reversible plasma
protein binding following toxic and nontoxic doses suggests the reason-
ableness of a rnreshold due to required saturation of anion binding sites
on plasma proteins following toxic doses thus making more free furosemide
available for metabolic conversion. 79 These general effects were found
with several simple furan compounds and furan itself. The study by
Guengerich84
 also noted threshold effects but at the same time found
that doses nontoxic to rats could produce mutations in S. typhinurium.
Several authors have pointed out the carcinogenic/mutagenic potential
of furan compounds due to their alkylating abilities. 79'32-84
Current Standards
None found.
Recommendations
No data exist on which to establish a standard.
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HEXANE
Introduction
MOLFM: C6 H14	 MW: 86,17 d20 0,660
Solubility: relatively insoluble in water
Syn: N-hexane
used as a solvent
Metabolism
In guinea pigs injected ip with 132 mg/kg of hexane, the peak blood
concentration of 20 pg/l was reached in 30 min. 85 There appeared to be
a phase of rapid elimination with a half-life of 36 min ; followed by a
phase of slower elimination with a half-life of 4 hours. The metabolite
2-hexanol was found in groups treated with either hexane or MBK whereas
the metabolite ,25-hexanedione was found only in the MBK-treated group.
However, in vitro studies yielded both metabolites from both solvents.
Acute Effects
No acute effects were seen after exposure to 2000 ppm for 10 min.
whereas a dizziness resulted from exposure to 5700 ppm, 5 The LDLo
for ip injection in rats is reported to be 9100 mq/kg and the LCLo for
inhalation exposure in mice is reported as 120 9/m3,64
Chronic Effects
Hexane is apparently capable of producing a neuropathy characterized
as an axonal disease in which distal portions of sensory and motor axons
undergo a progressive retrograde degeneration with abnormally large
accumulations of 10 mm neurofilaments and focal axonal swelling with
thinning of the myelin, 
86 
It has been suggested that 1 1BK and n.hexane
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are biotransformed to the same metabolite(s) which may provide a
common basis for their neurotoxic action. 
87 
As noted in the section on
metabolism, Couri, et. al. 
25 
showed that there are two common metabolites
for both MBK and hexane.
Carcinogenicity/muta5enicity/teratogenecity
No reference in the available literature regarding these effects.
Current Standards
The OSHA standard set in'1974 gave a TWA of 500 ppm88 but a
later criteria document for occupational exposure to alkanes recommends
a TWA of 350 mg/m3 . 3 No water quality standards exist for hexane.
Recommendations
The neuropathic effects of hexane suggest a conservative standard.
We consider that 1 mg/l hexane in water would provide adequate protection.
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METHANE, DICHLORO
Introduction
MOLFM: CH2 C1 2 MW 84.94 d20 1.3255
Solubility: relatively soluble in water
	
Syn:	 methylene chloride, methylene dichloride (-bichloride)
Found in finished water supplies as a result of the chlorination
process 9d
Literature: Many reports are available but most deal with vapor
exposure.
Metabolism
Methylene chloride has been found to be eliminated from the body
primarily unchanged in expired air within about two hours. 9, 90
Approximately 2,10 was considered to be left in the liver, kidney and
adrenal glands after 24 hrs. by DiVincenzo and Hamilton 
89 
whereas
Carlsson and Hukten 9O characterized the residual as being primarily in
white adipose tissue. Both papers report minor CO production. DiVincenzo
and Hamilton report that after 24 hours, 91.5 y of methylene chloride was
expired unchanged, 2p
 as CO, 3% as CO 2' 1.5b uncharacterized and 1" in
the urine. This same report mentions increases in serum formaldehyde
related to a decrease in liver formaldehyde but states that it must be
a physiological induction and not a metabolite but this was Tatar disputed. 91
Apparently methylene chloride is not inducible by itself or with oheno-
0
	barbital	 or 3-MAC
	
but does require NADPH and molecular 02 3
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Acute Effects
An acute oral (low) for humans has been reported to be 500 mg/kg,5
for rats (LD50, oral) 1.6-2.3 ml/kg. 94 The intraperitoneal L050 for mice
and dogs are given as 1.50 ml/kg and 0.95 ml/kg respectively. 95
Chronic Effects
Rats given drinking water containing 125 u g/l for 91 days showed
no adverse effects. 
96 
Inhalation exposures for 6 months at a concentration
of 5,000-ppm produced no effects in dogs and rabbits. 9d CNS effects
have been seen in humans at exposures over 300 ppm 97 and seen to be one
of the more sensitive parameters of exposure. Most of the CNS effects
appear to be readily reversible upon removal from exposure. These CNS
effects may be strongly related to CO production from metabolism of
methy l ene chloride. There is some concern that methylene chloride may
prolong the half-life of CO 
98 
but this has been recently disputed. 99
However, the potential for additive effects between dichloromethane and
CO is sufficiently strong that NIOSH has set a TWA of 75 ppm which must
be lowered if exposure to CO also occurs. 97
Carcinogenicity
Using strain A mice and the pulmonary tumor induction technique,
dichloromethane gave elevated though nonsignificant tumor numbers. 100
The authors felt that the nonsignificance may be due to low numbers of
test animals and that further testing should be done.
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Teratogenic/Embryotoxic Action
Mice and rats exposed to 1225 ppm dichloromethane for 7 hours daily;
days 6-15 of gestation gave no signs of maternal, embryonal of fetal
toxicity as well as no signs of teratogenicity.101
Mutagenicity
Negative results were obtained in a Drosophila test 
102 but transforming
activity has been shown in a system using Fisher rat embryo cells at
concentrations as low as 1.6 x 102 um 103
Current Standards
The current NIOSH standard is a TWA of 75 ppm.
No drinking water standards exist.
Recommendations
We consider that a standard 1.0 mg/l methylene chloride in drinking
water should provide adequate protection to exposed populations.
a
METHANE, DICHLORODiFLUORO-
Introduction
MOLFM: CC1 2 F2 MU 120.91 d^? 9.8	1.486
Solubility: very soluble in water
S,yn:	 Fluorocarbon 12, Freon-12, Propellant-12, Refrigerant 12,
Arcton 6, Halon
Used as a refrigerant or aerosol propellant
Literature: a large number of reports are available nut most deal
with inhalation exposures
Metabolism
A study using a fixed volume of inhaled, labeled dichlorodifluoro-
methane over a 7-17 min. period found less than 0.2 1/0 of the administered
dose in the urine or exhaled as CO2 ,
104
 Similar results were noted in dogs. 105
Dichlorodifluoromethane has a blood-gas partition coefficient of 0.2 which
helps to explain its rapid elimination via expired air. Another study
found F12 in the cerebrospinal fluid one minute after start of inhalation
but all was essentially gone 20-25 min post exposure. 
106 
Another study
found less than 1% of the administrated dose in tissues 24 hours. after
exposure. 
107 The addition of fluorine atoms to the dichloromethane
molecule greatly stabilizes the molecule and accounts for its.slight
metabolism.
Acute Effects
There has been some concern with the sudden death that occurs in
youths breathing dichlorodifluoromethane. At a tissue bath concentration
of 1.06 mg/100 ml, F12 produced a 20% depression in amount and rate of
isometric force development in heart Atria. 
108 
Another report states
{a:
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that cardiac output was decreased by 10-20" FC 12 after 12-30 min.109
Some studies have reported ECG changes whil_ others have not. 110 They
possibility of interaction with other drugs in FC 12 sniffing youths
should be considered more thoroughly.
Chronic Studies
An inhalation study exposing test species to 3997 mg/m 3 continuously
for 90 days resulted in the death of 2/15 guinea pigs, 0/3 rabbits, 0/2
dogs and 0/2 monkeys. ill Varying degrees of lung congestion and fatty
infiltration of the liver were noted. Both male and female rats exposed
in utero were also exposed for two years by intragastic intubation at
doses of 11-25 mg/kg and 130-256 mg/kg. 112 There were essentially no
clinical signs of toxicity or teratogenicity, nor was reproduction or
lactation interfered with. The dominant lethal mutation index was not
affected. Dogs fed for 2 years on diets resulting in exposures of 10 mg/
kg and 100 mg/kg showed .io signs of toxicity. Rats, mice and dogs exposed
to 164-2240 mg/kg/day for 2 weeks to 23 months showed signs of sedation,
ataxia and mild depression only at the highest doses which would disappear
rapidly after ending exposure.
	
Gross and microscopic examination gave
no signs of toxicity.
Current Standards
Dichlorodifluoromethane has an aquatic toxicity rating of >1000 ppm
and a NIOSH standard TWA of 1000 ppm.64
Recommendations:
We consider that a standard of 1 mg/l dichlorodifluoromethane in
drinking water will provide adequate protection from recognized hazards.
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METHANE, I00o-
Introduction
MOLFM: CH3	 2I	 MW: 141.94 d20 2.28
Solubility: slightly soluble in water
Syn:	 Methyl iodide
Used as a methylating reagent in the chemical industry.
Literature: Small number of articles available but oral administration
is covered.
Metabo.i i sm
An inhalation study in humans has shown that very little iodomethane
is excreted via the lungs once i t has entered the blood-stream. 113
A study of oral dosing in rats found that of a 50-15 mg/kg dose, 40-50%
has apparently reacted with GSH within 1.5 hrs. and 22-28% was excreted
in the bile within 6 hrs. 114 Smaller amounts of methyl mercapturic acid,
methylthioacetic, N-(methylthioacetyl) glycine and S-methyl-L-cysteine
have been found in the urine and may be the products of kidney metabolism
of any S-methyl glutathione that reaches them. 115
Acute Effects
Acute effects are associated with congestive changes in lungs, oliguric
renal failure, prominent cerebrellar and Parkinsonian neurologic symptoms
as well as seizures and coma. 116 psychiatric disturbances may occur for
months to years. Although there has been a fair number of poisoning
cases by other monohalide urethanes, the low usage of iodomethane has
resulted in very few cases of acute poisoning in humans. An oral dose
of 75 mg/kg is sufficient to produce an L050 in rats 
114 
whereas an oral
dose of 0.35 mmoles/kg was found sufficient to reduce liver glutathione
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levels to 58% of control values. 
117 
Experimental reduction of liver
glutathione levels can reduce the excretion of several compounds,118,119
and potentiate the toxicity of dimethyl phosphorothionates.120
Chronic Effects
As reported earlier, an oral dose of 75 mg/kg is sufficient to
produce an L050 in rats, 114 yet in the same study, it was reported that
an oral dosing of 30-50 mg/kg, 5 days/week for a month produced no signs
of toxicity. This was attributed to the rapid turnover of rat glutathione
(t-^ = 3-4 hrs.) thus the animals had sufficient time to overcome
accumulative effects.
Carcinogenicity
A 24 week study involving 24 ip injections for a total of 0.06
mmoles iodomethane/kg resulted in a survival rate of 19/20 mice with a
nc:isignificant increase in lung tumors whereas a total does of 0.31
mmoles resulted in a p<0.05 significant increase in mortality. 121
Another study dosing with 50 mg/kg in a sin g le subcutaneous injection
or in 10 mg/kg weekly doses resulted in massive local sarcomas.122
Another report states that subcutaneous injections will produce local
sarcomas but that none were seen by intravenous or oral routes of
administration in rats. 123
Current Standards
The current OSHA air standard is a TWA OF 5 ppm.124
Recommendations
We consider that a standard of 1 mg11 iodo-methane in drinking water
will provide adequare protection from recognized hazards.
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PROPIONIC ACID, METHYL ESTER
Introduction
MOLFM: C4 H8 02	MW 88.12 d26 0.9151
Water solubility: relatively soluble
Syn: (Propanoic acid, methyl ester), methyl propionate
Literature: essentially no literature appears to be available
regarding physiological actions.
Metabolism
No studies reported in the available literature
Acute Effects
The LDLo for an oral dose in rabbits is given as 2550 mg/kg.64
Chronic Effects
No studies reported in the available literature.
Current Standards
None noted.
Recommendations
It is impossible to recommend a standard on this substances without
further documentation.
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TOLUENE
Introduction
MOLFM:	 C2 Ha MW:92.13	 040	 0.8669
Water solubility: relatively insoluble
Syn:	 Methyl)enzene, phenylmethane
Used as solvent.
Found at concentrations up to 11 ug/L in New Orleans are a drinking
water. 9e
Literature: a large volume of literature is available.
Metabolism
It is estimated that from 75-90% of the absorbed toluene is excreted
via the urine as metabolized products and theiest excreted via the lungs
as unchanged toluene. 125-127 The general sequence of metabolism is toluene -3
benzyl alcohol 4 benzaldehyde -j benzoic acid followed by conjugation
primarily with glycine giving hippuric acid and a smaller amount with
glucuronic acid giving benzoylglucuronic acid. 
130 
After oral administration
to rats, maximum levels were reached in most tissues within 2-3 hours
with the exception of white adipose tissue where maximum levels were
reached 5 hrs. following dosing. 
139 
This same study found that maximum
levels were reached in most tissues 15-30 min. followinga brief inhalation
exposure. During the first 9 hrs. following ex posure, toluene was more
rapidly eliminated following inhalation exposure but tissue levels were
essentially the same by 12 hrs. post exposure. Elimination was much slower
from white adipose tissue and bone marrow concentrations only showed a
slight decrease in 24 hrs. These general trends have been found in other
studies 132, 133
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Acute Effects
Acute effects can range from irritability and deminished psychomoter
performance to disorientation and unconsciousneEs. 134 There have also
been reports of "sudden sniffing death" perhaps associated with an
increased sensitivity of the mammalian heart to epinephrine. 135 The
calculated LC50 for inhalation exposure using rats is 8800 ppm. 136
References are cited for a LDLo in a human oral exposure of 50 mg/kg
and an oral LD50 in rats of 5000 mg/kg in the Registry of Toxic Effects
of Chemical Substanc=.,s 64
Chronic Effects
Mice exposed for 3 hr/day, 5 days/week, for 8 weeks at 4000 ppm showed
signs of intoxication but no mortality nor was there evidence of damage
to lungs, liver or kidneys. 139 No significant effect was seen in rats,
guinea pigs, dogs or monkeys exposed to 1085 ppm toluene for 30 sessions. l'8
Rats and beagles exposed from 240 to 980 ppm for 6 hrs./day for 13 weeks
showed no significant chan0es in hematology, clinical chemistry or micro-
pathology.
136
 In workers exposed to an average of 200 ppm for 3-15 years,
a slightly higher but nonsignificant occurrence of unstable.chromosomal
abberations was noted. 139
Carcinogenicity
Tcluene was reported to be an enhancing agent for skin carcinogenesis
but this may be the result of a general irritancy effect with hyperplasia
following. No references to systemic carcinogenicity were noted ty several
recent review authors,9e, 140, 141 No references to mutagenicity,
NAS9-15368
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teratogenicity or embryotoxicity are noted at this time.
Current Standards
NIOSH currently recommends an 8-hrs. T14A of 100 ppm with a 200 ppm C.134
No recommendation for a water standard was made in a recent review. 9e
Recommendations
We consider that a standard of 1 mg11 toluene in drinking water
will provide adequate protection from recognized hazards.
^4
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XYLENE
Introduction
MOLFM:	 C8 H10 'MW: 106.16 d20 - 0.86
Water solubility: relatively insoluble
Syn:	 dimethyl benzene, xylol
Exists in three isomeric forms (ortho, meta, para); most products are
composed primarily of the meta isomer.
Used as a solvent.
Found as high as 4.1/ug/liter in finished water of the New Orleans
area. 9f
Metabolism
Most of the aromatic solvents become absorbed onto red blood cell
membranes and plasma lipoproteins and are then transported to other tissues
where they accumulate in proportion to the fat content of the tissue.
Unchanged aromatic solvents are expired in proportion to their vapour
pressure and blood concentration. Xylene's low vapor pressure results
in relatively little of the absorbed dosage being exhaled as unchanged
xylene. In man, it has been estimated that 12/00 of the absorbed m-xylene
was excreted as m-methyl hippuric acid within 18 hrs. 143 Another report
gives 90.1. of the absorbed xylene as being metabolized. 14 2 This latter
report studies the kinetics of excretion of ingested m-methyl hippuric
acid and found the same rate of excretion, followed by conjugation with
glycine, thus concluding that the metabolism of xylene occurred very rapidly.
A study in rats showed that phenolic metabolites accounted for < l; of a
100 mg/kg dose. 144
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Acute Effects
Acute effects include a narcotic-type action and muscular weakness.
The oral L050 in rats is reported as 4.3 g/kg; 145 the ip. L050 in
mice as 1.5 g/kg; 144 the inhalation LC50 in rats for a 4 hr. exposure
as 6700 ppm. 146 One study giving 1 g/kg by either stomach intubation
or ip. injection found a 65-70 y reduction in -xylene hydroxylase microsomal
activity in the lungs. 
147 
is was speculated that an unidentified, NAOPH-
requiring interactior, between p-tolualdehyde and the endoplasmic reticulum
was taking place. It has been estimated that the LOLO for the oral route
in humans is 50 mg/kg.15
Chronic Effects
In beagles and rats exposed 6 hr/day, 5 days/week for 13 weeks to
180-810 ppm xylene levels, no significant changes were found when blood,
urine, body weight or microscopic tissue parameters were examined. 146
No significant effects were found in the hematopoietic system of experi-
mental animals doses up to 100 mg/kg/day for 9 weeks. 148 In rats and
rabbits dosed with 690 ppm for 8 hr./day, 6 days/week for 130 days
there were no significant deviations in peripheral blood parameters. 149
Another study found no significant changes in hematologic parameters
in rats, dogs, guinea pigs or monkeys. 150
Carcinogenicity
Xylene application to the skin can increase the tumour yield of
subsequent urethane application, 151 but these effects may be related to
the general irritancy and subsequent skin hyperplasia seen with several
A-37
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solvents. 
152 
This latter review found no mention of systemic carcinogenicity
by xylene.
Mutagenicity
No reports of mutagenicity were noted in two recent reviews. 9f, 152
Teratogenicity
When tested as a mixture with an emulsifier, xylene showed no embryo-
toxic or fetotoxic effects. However, there is a report that xylene may
produce developmental defects in chicken embryos. 153
Present Standards.
The current MIOSH standard for an 8 hour TWA is 100 ppm with a ceiling
s
of 200 ppm. 154
 However, the authors of this report felt that sufficient
epidemiological studies had not been performed to adequately support
this limit but there were several experimental studies that suggested that
it may be adequate. A recent study committee did not recommend a water
quality standard without further research into chronic effects of low
level exposure. 9f
Recommendations:
We consider that a standard of 1 mg/l xylene in drinking water will
provide adequate protection from recognized hazards.
RM
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APPENDIX IV
TABLES I THRU VI
FIGURES 1 THRU 4
SCHEDULE FOR ESTABLISHING POTABLE
REUSE WATER QUALITY CRITERIA FOR
MANNED SPACEFLIGHT
.L,
NAS9-15368
TABLE I
VCD CONDENSATE
VOLATILE ORGANIC ANALYSIS SAMPLES
Date Time Date
)llected Collected Analyzed Sample History
) Mar 78 0900 21 Jun 78 40C( 22d);Iodated;23OC(10d);40C(82d)
) Mar 78 1500 22 Jun 78 40C 105d)
L Mar 78 1G00 1 Apr 78 40C 18d
) Mar 78 1400 22 Jun 78 40C 19d
118d
;	 Iodated;23oC(83d)
1 Mar 78 1400 1 Apr 78 40C
1 Mar 78 1400 10 Apr 78 40C 18d ;	 Iodated;230C(10d)
i Mar 18* 0900 21 Jun 78 40C 99d
i Mar 78 1054 1 Apr 78 40C 16d
198d)i Mar 78* 1100 21 Jun 78 40C
i Mar 78 1500 1 Apr 78 40C 16d) -
' Mar 78 0900 1 Apr 78 40C 15d)
' Mar 78 0900 10 Apr 78 40C 15d);Iodated; 230C(10d)
Mar 78 1100 1 Apr 78 40C 12d)I Mar 78 1100 10 Apr 78 40C 12d ;Iodated;	 230C(10d)
I Mar 78 1400 21 Jun 78 40C(12d);Iodated; 230 C(10d);	 40C(72d)
iTE: Distilled water from NASA-JSC was used as an
analytical blank for the non-iodated VCD sam-
ples. This water was iodated to serve as a
blank for the iodated VCD samples.
arbon balance samples
xxd) = days at indicated temperature
NAS9-15368
TABLE II
VCD CONDENSATE SEMI-VOLATILE
ANALYSIS SAMPLES
Date Time Date
Collected Collected Extracted Sample History
8 Mar 78 1500 Composite 1 Apr 78 40C(24d)9 Mar 78 1100 N1
13 Mar 78 1400 Composite 1 Apr 78 40C(19d)
14 Mar 78 1100 N2
15 Mar 78* 0900 20 Jun 78 40C(99d)
16 Mar 78* 1100 20 Jun 78 40C(98d)
15 Mar 78 0900 Composite 1 Apr 78 40C(17d)
16 Mar 78 1000 N3 1 Apr 78
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TABLE III
PRECISION COMPARISON FOR TWO CONCENTRATORS
% Relative Standard Deviation (1a) *
S pectrix Unit (1)	 Tekmar Unit
trans-1-2,dichloroethylene 12 9.7 5.3 N/A N/A N/A
carbon tetrachloride 2.5 13 3.0 4.3 18 2.5
cis- 1 9 2-dichloroethylene 7.7 11 4.4 N/A N/A N/A
chloroform 2.3 4.1 4.4 27 8.2 0.1
T.,1,1- trichloroethane 1.4 4.3 4.2 N/A N/A N/A	 1
R
5romodichloromethane 1.4 5.0 5.2 8.8 9.2 2.2
tetra chlo roe thylene 9.0 30 4.1 3.2 21 9.3	
5
1 9 2-dichloroethane 1.3 5.1 2.4 3.9 6.3 2.1
chlorodibromomethane 14 14 4.6 10 8.9 2.2
trichloroethylene N/A N/A N/A 22 23 1.5
1,1,1-trichloroethane 1.0 7.4 1.2 9.1 17 4.8
rromoform 20 32 5.7 17 9.4 5.7
-dichlorobenzene 29 23 N/A N/A N/A N/A
;1) Data obtained with 25 ml samples using a GC-MS detector.
;2) Data obtained with 10 ml samples using GC-MCD.
All values obtained from five replicate analyses
I/A - No data available
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Concentration	 in	 /L	 (PPB)-
TABLE	 IV ^,	 * a	 *	 o
Volatile Organic Analysis Results ,.: a	 F	 o
JL
DATE TIME REMARKS u °	 u	 a'	 a	 '0	 a °'	
a	
•^	 '^' z
:	 Tables
	
I	 &	 II
-0.	 "	 v	 °' °	 'c	 V	 a
cz,	 o	 Q	 i `'	 Q b	 „	 ^
3-10-78 0900 40C after iodation 5.9 38 1.9 T 86
3-10-78 1500 long storage 1.5 22 2.4 3.3 8.8 25
3-11-78 1000 short storage 15 1.1 1 6 T T
3-13-78 1400 40C after iodation 6.8 2.3 T 14
3-14-78 1400 short storage 2.1 0.9 1.6 T
3-14-78 1400 iodated 2.4 0.5 T 1.4 T
3-15-78 0900 long storage 6.3 29 5.1 T 250
3-16-78 1100 long storage 6.2 17 T T 7.2
3-16-78 1500 short storage 28
3-17-78 0900 short storage 20 10 1.6 16 1.6 42
3-17-78 0900 iodated 8 11 1.5 15 1.5 40
3-20-78 1100 short storage 16
3-20-78 1100 iodated T 14 T
3-2C-78 1400 40C after iodation 3.5 15 T T 7 0
3-31-78	 blank
4-1-78	 liodated blank
*Quantitated from relative response factors/ T = 0.1 - 1.0 vg/L TBD = to be determined but <10
Blank indicates not detected at the indicated detection limits
KAS9-15368 SPECTRIX CORPORATION
7406 FAMM M	 NOUSTON. TEXAS 77094
Concentration in Ng
TABLE	 IV	 (continued) V
C	 C	 .^	 v	 ~ y	 ^ L
N	 o a s '^
Ac
ti
DATE TIME REMARKS
See Tables	 I	 &	 II
3 - 1 0-78 0900 40 after iodation 1.0 3.8 7.0 T
3-10-78 1500 lone storage 1.3 4.4 1.1 5.5 T
3-11-78 1000 short storage T 170 T
3-1 l-78 1400 40C T T
3-14-78 1400 short storage 70
3-14-78 1400 iodated T
3-15-78 0900 long storage 11 4.4 31
3-16-78 1100 long storage 1.2 2.4
3-16-i8 1500 short storage 9
-17-78 0900 short storage 176 T
3-17-i8 0900 iodated T
3-20-78 1100 short storage 19
3-20-78 1100 iodated 17
3-20-78 1400 40C after iodation 1.3 3.1 5.2 10
3-31-78 blank
4-1-78 iodated blank
Detection Limits	 004 1 TBD 1 0.1 jTB9
	 TBD
	
TBD
* Quantitated from relative response factors / T = 0.1 - 1.0 Ng/L	 TBD = To be determined but <10
Blank indicates not detected at indicated detection Limits
NAS9-15368
TABLE V
RESULTS OF SEMIVOLATILE EXTRACT ANALYSES
Component Identified
dimethyl phthalate
diethyl phthalate
di-n-butyl phthalate
butyl benzyl phthalate
bis(2•-ethylhexyl) phthalate
Quantity (Vg/L = PPB)
0.9
3.7
2.0
3.4
14
Sample I.D.
3/8 - 3/9 Composite
3/13 - 3/14 Composite dirm?thyl phthalate
diethyl phthalate
di-n-butyl phthalate
butyl benzyl phthalate
bis(2-ethylhexyl) phthalate
1,4
3.1
17
2.0
15
3/15 - 3/16 Composite
	 diethyl phthalate
	
4.7
di-n-butyl phthalate
	
26
butyl benzyl phthalate
	
2.0
bis(2-ethylhexyl) phthalate	 28
NAS9-15368
TABLE VI
SUGGESTED RECLAIMED POTABLE WATER QUALITY SPECIFICATION
APPEARANCE
Color - 5 on cobalt scale
Total solids - less than 500 ppm
PALATARTI.I; •
Dissolved gases
CO 2 :	 1-5 ppm
0 2 :	 1-5 ppm
Chemical Constituents - Inorganic
Ca ++ :	 20±5 ppm	 Cl-:
Mg ++ , Na + :	 10 ±2 ppm	 SO4=, NO3R:
K+ :	 211 ppm	 HCO3s1 CO3=:
Chemical Constituents - Organic
Nonvolatile
Total Organic Carbon (TOC):
Dissolved Organic Carbon (DOC):
Particulate Organic Carbon (POC):
Volatile Compounds
30=10 ppm
40 ±10 ppm
10 ±5 ppm
<1 ppm
<1 ppm
<1 ppm
Compo nent 	 Upper Limit (mg/L or ppm)
Acetone 50
Benzene 0.1
Carbon	 disulfide 0.05
Chloroform 0.1
Dioxane 1.0
Ethane,	 1 ,1 ,1 -tr ichl oro .0
Hexane 1.0
Dichloromethane 0.1
Dichlorodifluoromethane 1.0
Methyl	 iodide 1.0
Toluene 1.0
Xylene 1.0
1,2-Dithiolethane TBD
2-tlethyl	 furan TBD
Methyl	 acrylate TBD
Rotameter
Back-Up Tenax Trap
TefTon Sleeve
Primary Tenax Trap
0-ring seal
Purging Chamber
Fritted Disc
He
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FIGURE 1
SCHEMATIC OF PURGING APPARATUS
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SAMPLE. NASA BN FRAC. 3/13 a 3/z4
RANGE: G
	 1, 838 LABEL: N 0, 4.0 QUAN: A 0,
OATA: 144R135N #1
	 B^ANS
	 50 R] 838
c*LI: 144R13BN #3
BASE: U 20, 3
58560.
72
RIC
Schedule
	
for
	 Establishing	 Potable Reuse Water Quality Criteria 	 for Manned	 Spaceflight
ask or	 Description 1979 1980 1981 1982 •1983
Mile 1 2 3 4 112 3 14 1 2 3 4 1 2 3 4 112 3 4
tbne
No.
T1 Development Contractor Procurement
M1 Award Development Contract
Organize Review Committee
J3 Task Group Preparation for	 Initial
Review Committee Meeting
M2 Initial	 Review Committee Meeting
T4	 10evelopment of Health Effects Research
Plan
M3 Second Review Committee Meeting
T4 Health Effects Research
T5 Develop Flight Qualification	 Test	 P)an
M4,5 Review Committee Annual Meetings
T6 Prepare Water Quality Criteria
Qua lityCr i teria	 to Review
CIDmmittee
T7 evise Water Quality Criteria
M7 inal	 Approval	 of Water Quality Criteri a
1 = 1st Quarter	 3 = 3rd Quarter
2 = 2nd Quarter	 4 = 4th Quarter
